Kornimate/medical-research-clean huggingface dataset:
patient-ventilator asynchrony in conventional ventilation modes during short-term mechanical ventilation after cardiac surgery

Conditions: Thoracic Surgery

Summary: this study evaluates the effects of vcv, pcv and psv ventilatory modes during the immediate postoperative period on the variables resulting from regional and global pulmonary electrical impedance and diaphragmatic mobility, as well as perform ventilator synchrony analysis in psv mode by mechanical ventilator. half of the participants will receive vcv followed by psv for weaning, while the other half will receive pcv followed by psv for weaning.

in the immediate postoperative period of cardiac surgery, patients are found under mechanical ventilatory support. commonly, they are ventilated in controlled and assisted-controlled volume (vcv) or pressure (pcv) modes, with weaning at pressure support (psv). systematic reviews indicate that there is no difference between the vcv and pcv ventilatory modes for some clinical outcomes or that the existing evidence is insufficient. the distribution of regional ventilation and diaphragmatic mobility can be measured from the use of electrical impedance tomography (eit) and diaphragmatic ultrasonography (us) to clarify the physiological changes and / or mechanisms of adaptation of the organism submitted to controlled modes cycled at volume or at pressure and spontaneously flow cycled mode. besides eit and us measures, gasometric, hemodynamic and respiratory data will also be recorded. the statistical analysis will be considered α≤0.05 for a statistically significant difference.

Eligibility criteria:
inclusion criteria: * imc 18.5-29.9 kg/m² * two thoracic tubes (one mediastinal and one left-sided pleural) * under mechanical ventilation after surgery * submitted to intraoperative extracorporeal circulation exclusion criteria: * over 2h of cardiopulmonary bypass * over 12h of post-operative mechanical ventilation * post-operative bleeding above 500 ml in the first hour or above 300 ml in the first two hours * history of special conditions (neuromuscular and chronic pulmonary disease, thoracic deformity, abdominal distension).
immuno-virological efficacy of combination with trizivir +tenofovir in multiresistant hiv patients

Conditions: HIV Infections

Summary: to evaluate whether the combined therapy of two nucleosides plus one nucleotide (trizivir + tdf) manages to keep cd4 lymphocytes stable in patients with hiv infection on antiretroviral treatment that present virological failure and multiple resistance to antiretrovirals.

this study has been designed to determine whether the use of a regimen based exclusively on ntri, containing tenofovir, zidovudine and lamivudine, is able to preserve immunological status in patients with detectable viral load for whom an efficacious salvage regimen cannot be designed, slowing the progression of the viral load and reducing antiretroviral treatment-associated toxicity. in order to complete the salvage regimen without increasing the number of tablets too much, trizivir plus tenofovir as investigational treatment will be used.

Eligibility criteria:
inclusion criteria: 1. age\>= 18 years. 2. hiv-1 infected patients. 3. patients on antiretroviral treatment including ntri + pi +/- nnrti +/- fusion inhibitors at inclusion in the study. 4. virological failure, defined as 2 determinations with viral load \>1,000 copies/ml in the last 6 months, during stable haart therapy over the previous 6 months. 5. genotype or phenotype resistance to three families of antiretrovirals (pi, ntri and nnrti) demonstrated in genotype study carried out in the last 48 weeks and defined as: * 3 or more tams of the following: m41l, e44d, d67n, v118i, l210w, t215y/f, k219q/e. * existence of the m184v mutation or probable presence in the cellular archives. * 5 or more mutations that confer resistance to pi of the following: i10f/i/r/v, v32i, m46i/l, i54v/m/l, v82a/f/t/s/v, i84v/a/c, l90m. * existence of 1 or more mutations that confer resistance to nnrti, or probable presence in the cellular archives of: k103n, y181c/i/y, g190s/a/g. 6. cd4 lymphocytes \>- 300 cells/mm3 in the last two determinations. 7. subject able to follow the treatment period. 8. acceptance of the study and signature of the informed consent form. 9. women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study. exclusion criteria: * suspicion of previous incorrect adherence. * pregnancy or breastfeeding * suspicion of intolerance to any investigational drug. * record of any disease which, according to clinical criteria, may reoccur with the proposed change of therapy (sarcoma, lymphoma, etc). * cd4 nadir below 200 cel/mm3. * acute intercurrent disease or fever in the 15 days before inclusion.

Keywords: antiretroviral treatment virological failure hiv
a study of kc1036 in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of kc1036 in participants with advanced recurrent or metastatic solid tumors. the trial will be divided into three parts: dose-escalation phase, dose-expansion phase, rp2d-extension phase.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed recurrent or metastatic solid tumors; * patients who have failed standard or conventional treatment, including chemotherapy, targeted therapy, immunotherapy: documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant/neoadjuvant therapy; * at least one measurable lesion (by recist 1.1); * eastern cooperative oncology group performance status score of 0 or 1; * life expectancy \> 12 weeks; * patients should participate in the study voluntarily and sign informed consent. exclusion criteria: * untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks; * other kinds of malignancies; * hematologic, renal, and hepatic function abnormities; * risk of bleeding; * gastrointestinal abnormalitiest; * cardiovascular and cerebrovascular diseases; * prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks of enrollment; * presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to nci ctcae v5.0 grade 0 or 1 with the exception of alopecia; * involved in other clinical trials within 4 weeks of enrollment; * major surgical procedure, open biopsy, or significant traumatic injury 4 weeks days of enrollment; * history of organ allograft; * need immunosuppressive agents or systemic or absorbable topical hormone therapy for immunosuppression; * uncontrolled ongoing or active infection; * known history of human immunodeficiency virus (hiv) infection or current chronic or active hepatitis b or c infection requiring treatment with antiviral therapy; * pregnant or lactating women or those who do not take contraceptives, including men; * suffering from mental and neurological diseases; * any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings; * inability to comply with protocol required procedures.
new treatment for donor sites

Conditions: Burn

Summary: primary research questions/purpose of the research. 1. determine the short term (epidermal regeneration, reduction of pain, infections and length of stay) and long term (scarring, long term recovery, and cost of treatment) outcomes of microbial nanocellulose (nc) and fine mesh gauze impregnated with hyaluronan and thrombin (ht). 2. determine if donor site treatment with nc and ht is as safe as the use of scarlet red ointment dressing. b. describe the importance of the knowledge that you expect to gain from the research. to find a donor site dressing that has outcomes equal or better than that of scarlet red.


Eligibility criteria:
inclusion criteria: * ages 0-90 years. * any patient admitted to the hospital with burn injury requiring grafting and a donor site. exclusion criteria: * patient with severe burn injuries expected to die.

Keywords: burn donor site grafting scar
a trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted globally. the aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * male or female diagnosed with type 2 diabetes * age at least 50 years at screening and presence of cardiovascular disease, or age at least 60 years at screening and presence of at least one cardiovascular risk factor exclusion criteria: * current or previous (within 90 days prior to screening) treatment with any glp-1 (glucagon-like peptide-1) receptor agonist, dpp-4 (dipeptidyl peptidase-4) inhibitor or pramlintide * family or personal history of multiple endocrine neoplasia type 2 (men 2) or medullary thyroid carcinoma (mtc) * history of pancreatitis (acute or chronic) * history of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) * subjects presently classified as being in new york heart association (nyha) class iv heart failure * planned coronary, carotid or peripheral artery revascularisation known on the day of screening * any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 60 days prior to screening * chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment (corresponding to egfr (glomerular filtration rate, estimated) below 30 ml/min/1.73 m\^2) * history or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)
alogliptin tablets special drug use surveillance "type 2 diabetes mellitus: monotherapy/combination therapy with α-gi"

Conditions: Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution

Summary: the purpose of this study is to determine the safety and efficacy of long-term treatment with alogliptin (nesina) in patients with type 2 diabetes mellitus who responded inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. in addition, examining the safety and efficacy of alogliptin in patients with renal impairment, information on the appropriate dosage of alogliptin according to the severity of impaired renal function should be collected.

a special drug use surveillance is planned to examine the safety and efficacy of long-term use of alogliptin in patients with type 2 diabetes mellitus under the daily clinical use conditions. participants of this surveillance will be patients with type 2 diabetes mellitus who failed to respond adequately to diet therapy and exercise therapy alone or to a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. the planned sample size is 3,000 subjects. the usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily. participants will receive the drug as part of routine medical care.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus who have not adequately responded to any one of the following therapies: 1. diet therapy and exercise therapy alone 2. in addition to diet therapy and exercise therapy, use of α-glucosidase inhibitor exclusion criteria: * patients contraindicated for nesina 1. patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus (these patients require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of nesina is not appropriate.) 2. patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury (blood glucose control by insulin injection is desirable for these patients, and hence use of nesina is not appropriate.) 3. patients with a history of hypersensitivity to any ingredient of nesina

Keywords: drug therapy
the correlation between fasicitis plantaris and hallux rigidus

Conditions: Hallux Rigidus; Fasicitis Plantaris

Summary: comparison between 3 groups: * group i has hallux rigidus. is fasicitis plantaris present? * group ii has fasicitis plantaris. does the hallux have limited mobility? * group iii does not have hallux rigidus or fasicitis plantaris


Eligibility criteria:
inclusion criteria: * hallux rigidus or fasicitis plantaris or healthy volunteer exclusion criteria: -
assessment of the prevalence of olfactory disorders in systemic scleroderma

Conditions: Olfactory Disorders; Scleroderma

Summary: prospective monocentric study of patients with systemic sclerosis disease. the primary outcome is to define the prevalence of olfactory disorders (hyposmia and anosmia) in systemic sclerosis disease. the secondary outcomes are: * to assess the correlation of olfaction disorders with clinical and biological and factors related to systemic sclerosis patients. * to estimate the frequency of sinonasal disorders in patients with systemic sclerosis disease


Eligibility criteria:
inclusion criteria: * men and/or women * with systemic sclerosis disease * patient willing to comply with all procedures of the study and its duration * social insured patients exclusion criteria : * patient with medical history of chronic rhinosinusitis (crs), previously known for olfactory disorders secondary to another etiology (skull base trauma, viral rhinosinusitis) * past history of sinonasal surgery * patient unable to receive informed information * refusal to sign the consent form * unwillingness or inability to follow the study procedures, in the opinion of the investigator * person deprived of the liberty * non-coverage by the social security insurance * person benefiting from a system of legal protection (guardianship...)
preventing hypotension in the spine during cesarean delivery.

Conditions: Anesthesia

Summary: examining the advantages associated with the utilization of noradrenaline in preventing spinal hypotension during cesarean births. this involves assessing the positive outcomes and potential benefits derived from incorporating noradrenaline into the medical approach.

spinal anesthesia is used during cesarean section to provide rapid onset and dense block of motor and sensory nerves, intraoperative analgesia, and help patients remain conscious (1,2).hypotension is common during induction of spinal anesthesia for cesarean delivery (cd) (3).if not promptly treated, a decrease in blood pressure (bp) can have deleterious effects, which include maternal nausea, vomiting, dizziness, and cardiovascular instability as well as decreased uteroplacental blood flow with resultant fetal acidosis, hypoxia, and bradycardia.in the last decade, the α-agonist phenylephrine (pe) has been the vasopressor of choice for the prevention and treatment of spinal induced hypotension (4).to prevent and treat postspinal anesthesia hypotension during cesarean section, vasopressors are recommended. vasopressors (especially potent α-adrenergic receptor agonists) help offset the decrease in arteriolar dilation and peripheral vascular resistance caused by sympathetic nerve blockade after spinal anesthesia and may be associated with decreased incidence of neonatal acidosis.(5,6). norepinephrine is another vasopressor that was recently introduced in obstetric anesthesia (7). norepinephrine is characterized by α-adrenergic agonistic activity in addition to a weak β-adrenergic agonistic activity; thus, norepinephrine is considered a vasopressor with minimal cardiac depressant effect(7).; these pharmacologic properties would make norepinephrine an attractive alternative to phenylephrine and ephedrine in obstetric anesthesia. although the use of norepinephrine for prophylaxis against postspinal hypotension has shown promising results,(7,8) evidence is lacking on the optimum dose for norepinephrine infusion during cesarean delivery.

Eligibility criteria:
inclusion criteria: * the subject is scheduled for elective cesarean section . * no obvious abnormalities in preoperative ecg, blood routine, electrolytes, and other tests. * asa class 1-3. exclusion criteria: * patients have body mass index (bmi) \>35 kg/m2. -patients are known hypersensitivity to any of the drugs that would be used in the study. - * severe cardiac, renal, lung, or liver diseases. * eclampsia or preexisting hypertension (baseline systolic blood pressure ≥160 mmhg) * hemoglobin \<7 g/dl, or fetal distress. * patients that are immunologically compromised. * sleep apnea syndrome or difficult airway. 8.preexisting hypoxemia (spo2\< 90 %). * patient refusal.
effect of nasal highflow on right heart function

Conditions: Pulmonary Hypertension

Summary: in this study effect of nhf on pulmonary thermodynamic parameters will studied.


Eligibility criteria:
inclusion criteria: * stable disease * hypoxemic respiratory disorder exclusion criteria: * decompensation * acute illness

Keywords: nhf pulmonary hypertension
study in infants (6-12 months) comparing two doses of a monovalent glycoprotein-conjugated (diptheria toxin -crm197) vaccine versus a tetanus toxoid-conjugated vaccine available for the prevention of haemophilus influenzae type b infections in china

Conditions: Haemophilus Influenzae Type b (Hib) Infection

Summary: this study will evaluate the safety and efficacy of two doses of two commercially available vaccines used to prevent haemophilus influenzae type b infections in children 6-12 months of age.


Eligibility criteria:
inclusion criteria: * infants 6-12 months of age. exclusion criteria: * prior hib vaccine administration. * history of serious reaction(s) following vaccination. * any vaccination within 14 days of study vaccination. * known or suspected immune impairment. * for additional entry criteria please refer to the protocol.

Keywords: haemophilus influenzae type b (hib) vaccine booster
use of a novel neuroplasticity-based neurobehavioral intervention for ptsd

Conditions: Anxiety; Depression

Summary: the present study will explore the effectiveness of a computer based neurobehavioral intervention in alleviating symptoms and improving emotion regulation in individuals with ptsd. it will increase understanding of psychopathology at a neural-circuit level and aid development of new non-pharmacological treatment for ptsd. the study is managed by the etkin lab at stanford university in california, but participants from the entire us are welcome to participate as the study is delivered online.


Eligibility criteria:
inclusion criteria: * current ptsd * internet access exclusion criteria: * lifetime psychotic disorder, * past-year substance dependence

Keywords: computerized neurobehavioral intervention
exploration of wrist soft tissue injuries associated with wrist fractures

Conditions: Triangular Fibrocartilage Complex Injuries

Summary: the purpose of this study is to describe and stage lesions of the triangular fibrocartilage complex (tfcc) in association with distal radius fractures. 20 patients with dorsally dislocated ao type a fractures of the distal radius with sufficient displacement (based of cadaveric data) will be included. after stability testing and wrist arthroscopy. the tfcc is explored through a volar incision and injuries were documented and repaired from this approach.


Eligibility criteria:
inclusion criteria: * age 18-65 * distal radius fracture * displacement \> 20 degrees of dorsal angulation exclusion criteria: * previous significant wrist injury * declines to participate * ulnar styloid fracture at base or proximal to it

Keywords: tfcc injuries distal radius fractures
evolution of eifl following ppv

Conditions: Epiretinal Membrane

Summary: various classification systems have been described for epiretinal membrane (erm). one of them is a new oct-based staging scheme based on displacement and reorganization of inner retinal layers called ectopic inner retinal layers (eifl). we evaluated pre-and perioperative factors related to time for evolution of eifl.


Eligibility criteria:
inclusion criteria: * patients undergoing idiopathic epiretinal membrane surgery exclusion criteria: * patients undergoing seconder epiretinal membrane surgery
internet-delivered cognitive behavior therapy for problematic alcohol use in a working life setting

Conditions: Alcohol Use Disorder; Alcohol Abuse

Summary: internet-based cognitive behavioral treatment (icbt) for mental health issues has been successfully implemented in routine health care and research indicates that icbt can also be applied to decrease problematic alcohol use in healthcare as well as working life settings. however, qualitative studies investigating the feasibility of implementing icbt in a working life context have been lacking. the current study will investigate the feasibility of delivering icbt for problematic alcohol use within an employee assistance program (eap), and will compare outcomes for icbt with face-to-face treatment in a naturalistic quantitative study. recruitment to the study follows employer contact with the eap regarding an employee's presumed problematic alcohol consumption, leading to a five-session in-person psychological assessment. all assessed employees recommended icbt or face-to-face treatment will be offered participation in the study. in addition to quantitative evaluation, interviews will be conducted with employees and their employer representatives following icbt to elucidate both stakeholders' experience and perception of icbt in the work life context. thematic analysis and grounded theory will be used to analyze the interview material. outcome comparisons between icbt and face-to-face treatment will be assessed quantitatively using a reliable change index and analysis of variance or other relevant statistical analyses such as multilevel modeling.


Eligibility criteria:
inclusion criteria: 18 years; access to the internet; problematic alcohol use assessed by a licenced psychologist; referred to treatment within a rehabilitation intervention initiated by the work-place; work-place covers treatment costs; exclusion criteria: not adequately fluent in swedish; drug use; suicidality; indications of excessive use of the internet and computer gaming and/or gambling;

Keywords: problematic alcohol use work life cognitive behavior therapy feasibility outcome employee assistance program internet qualitative quantitative
symbicort maintenance and reliever therapy - experience in real life setting in malaysia

Conditions: Asthma

Summary: the purpose of the study is to evaluate the satisfaction level of patients using the symbicort smart approach for their asthma management.


Eligibility criteria:
inclusion criteria: * diagnosis of asthma for past 6 months and treated with inhaled glucocorticosteroids for at least 3 months. * patients who asthma is classified as uncontrolled or partially controlled as defined by gina 2006 guidelines. exclusion criteria: * patients already on symbicort smart treatment. * patients who has respiratory tract infection 30 days before study enrolment.

Keywords: asthma